Episode 12: What's the Deal With Peptides?

In this episode, we dig into peptides—why they’re suddenly everywhere, why people are trying them, and why the online conversation often feels worlds apart from the medical one. We zoom out from the hype to explore what peptides actually are, why some have become blockbuster therapies, and how a mix of optimization culture, mistrust of institutions, and access issues has fueled a booming gray market. We also explore the key questions we think everyone should be asking before trying anything that’s framed as “natural,” “risk-free,” or “not really a drug,” and we discuss what this trend can teach us about informed consent, patient autonomy, and where medicine may be headed next.00:00 Podcast intro01:18 Meet the hosts01:21 Peptides topic setup02:01 Patient longevity story03:39 Why peptides hype05:11 Natural fallacy talk06:50 What is a peptide08:19 Peptide drugs history10:47 Why peptides booming12:06 Legal gray areas13:55 Why it went viral14:50 Optimization culture16:35 Distrust and marketing20:14 K shaped economy angle24:37 Nugget of truth26:44 Peptides are drugs28:56 Gray market risks31:30 Evidence categories32:49 FDA approved examples33:22 Immune booster peptide34:14 Growth Hormone Peptides35:00 Side Effects Reality Check36:49 Statins Versus Hype37:54 Retatrutide Triple Agonist38:59 Wolverine Stack Breakdown39:31 BPC 157 Claims40:35 TB 500 No Human Data43:17 Regulation Versus Wild West45:11 Why Patients Take Risks46:42 Doctoring With Empathy50:26 Informed Consent Gaps52:55 Framing Changes Decisions55:39 Peptides Future Outlook58:26 Fund Studies Faster01:00:05 Wrap Up And Disclaimer📖 Read the full episode summary, sources, and resources on our Substack: 👉www.theantisocialdoctors.com